Genscript Biotech stock
1548.HKHKSEGenscript Biotech Corporation, HealthcareISIN KYG3825B1059
48Score 48 out of 100, Weak
Price and trend
71 / 100
Price history
+84% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 48% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 48).
The price is 38% below its 52-week high. Largest decline in 11 years: 80% (July 2021 to June 2024).
Chart figures for advanced users
- SMA 50$4.61
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$2.61
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)48
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.35
- The lowest closing price of the last twelve months.
- Resistance$6.24
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Genscript Biotech Corporation belongs to the Biotechnology industry (Hong Kong SAR China) and, with a market value of $8.67B, is number 41 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $959.53M (up 61.4% year on year) and a loss of $532.83M.
- MEQIRI Score 48 out of 100 (Weak): rank 393 of 702 in Healthcare, median 53.
Show more
- Our model puts fair value at $4.38, with the price 8% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $843.01M, financial debt $258.84M (fiscal 2025).Stability 70
Weaknesses
- Loss-makingLoss of $636.4M over the last 12 months.Fundamentals 20
- Volatile share priceVolatility 77% a year over the last 12 months.
- DilutionShare count up 14% since 2020.Capital allocation 23
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Fairly valuedClosing price of 12 Nov 2026, used by the daily score.
In our model the price counts as cheap below $2.92 and expensive above $8.77 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 10%. At 11% the fair value would be $3.69, at 9% it would be $5.36.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 1.9% on the twelve months before. Revenue has grown strongly since 2013, at around 26% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 58%, operating 27%, net −56%. Last 12 months: net −75%.
Debt & balance sheet
Fiscal 2025The balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 24 Mar 2027in 131 days
- Last reported
- 16 Aug 2026EPS reported −0.46
Analyst estimates
Analysts have raised their 2026 earnings estimate by 106.2% since 22 Oct 2026.
- Earnings per share
- 0.01+106.2%
- Revenue
- $893.43M+0.5%
- Earnings per share
- 0.09+14.0%
- Revenue
- $1.2B+3.3%
MEQIRI has stored the estimates since 22 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Genscript Biotech
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 48
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Haisco Pharmaceutical Group002653.SZ $10.07B69
- Spyre TherapeuticsSYRE $9.77B48
- TG TherapeuticsTGTX $9.76B66
- Alteogen196170.KQ $9.26B57
- Praxis Precision MedicinesPRAX $9.08B42
- Krystal BiotechKRYS $9.06B66
- Protagonist TherapeuticsPTGX $8.77B68
- Asymchem Laboratories (Tianjin)002821.SZ $8.29B64
ETFs that hold Genscript Biotech
Held by 54 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 3.87% | 0.50% | €127.64M |
| Amundi MSCI China ESG Selection Extra UCITS ETF AccLCHI | 0.42% | 0.65% | €564.13M |
| iShares Edge MSCI EM Value Factor UCITS ETF5MVL | 0.41% | 0.40% | €1.51B |
Show 5 more
| UBS MSCI China Universal UCITS ETF USD disUETC | 0.35% | 0.30% | €132.6M |
| Deka MSCI China ex A Shares UCITS ETFEL46 | 0.34% | 0.65% | €73.86M |
| Amundi MSCI Emerging Markets SRI Climate Paris Aligned UCITS ETF DR (C)AMEI | 0.33% | 0.25% | €2.64B |
| Xtrackers MSCI China UCITS ETF 1CXCS6 | 0.23% | 0.65% | €1.51B |
| UBS MSCI EM Socially Responsible UCITS ETF USD accUETE | 0.21% | 0.24% | €2.86B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 13 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 16 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.